AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Werewolf Therapeutics Inc (NASDAQ:HOWL)
0.3513 USD
+0.007 2.122%Sponsored Reports
Loading...
| Previous Close (in USD) | 0.344 |
|---|---|
| Change | +0.007 2.122% |
| 52 W H/L (in USD) | 5.730/0.595 |
| EBITDA (in USD) | -72.647M |
| PE Ratio | -- |
| Volume | 1575775 |
| Diluted Eps TTM | -1.64 |
| Total Assets (in USD) | 126.929M |
|---|---|
| Total Liabilities (in USD) | 53.539M |
| Revenue TTM (in USD) | 1.143M |
| Cash (in USD) | 110.995M |
| Market Cap (in USD) | 49.810 M |
| Revenue Per Share TTM | 0.026 |
| Gross Profit TTM (in USD) | -52.244M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Werewolf Therapeutics Inc
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. The company's lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
Employees: 46
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Daniel J. Hicklin Ph.D. | Founder, CEO, Pres, Sec. & Director | 1964 |
| 2. | Mr. Timothy W. Trost CPA | CFO, Treasurer & Assistant Sec. | 1958 |
| 3. | Dr. Chulani Karunatilake Ph.D. | Chief Technology Officer | NA |
| 4. | Dr. Reid Leonard Ph.D. | Chief Operating Officer | 1959 |
| 5. | Dr. Cynthia Seidel-Dugan Ph.D. | Chief Scientific Officer | 1959 |
| 6. | Dr. Randi Isaacs M.D. | Chief Medical Officer | 1956 |
| 7. | Ms. Ellen A. Lubman M.B.A. | Chief Bus. Officer | 1976 |
| 8. | Dr. Daniel J. Hicklin Ph.D. | Founder, CEO, President, Secretary & Director | 1964 |
| 9. | Mr. Timothy W. Trost CPA | CFO, Treasurer & Assistant Secretary | 1958 |
| 10. | Dr. Chulani Karunatilake Ph.D. | Chief Technology Officer | 1959 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.330 0.758% | 43.45 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
0.000 0.000% | 43 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-7.360 1.604% | 462.17 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+2.010 0.331% | 612.07 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|
| Income Before Tax | -53.81M | -49.983M | -15.04M | -10.248M |
| Minority Interest | - | - | - | - |
| Net Income | -51.564M | -49.767M | -14.939M | -10.99M |
| Selling General Administrative | 18.696M | 14.818M | 5.763M | 3.596M |
| Gross Profit | 16.401M | - | - | - |
| Reconciled Depreciation | 1.104M | 0.216M | 0.15M | 0.025M |
| Ebit | -57.16M | -50.303M | -22.404M | -9.936M |
| Ebitda | -56.056M | -50.087M | -22.254M | -9.541M |
| Depreciation And Amortization | 1.104M | 0.216M | 0.15M | 0.395M |
| Operating Income | -56.056M | -50.087M | -22.404M | -9.936M |
| Other Operating Expenses | 72.457M | 50.087M | 22.404M | 9.936M |
| Interest Expense | 1.104M | 0.216M | 0.101M | 0M |
| Tax Provision | - | - | - | - |
| Interest Income | 1.908M | 0.104M | - | - |
| Net Interest Income | 1.908M | 0.104M | 0.101M | -0.372M |
| Income Tax Expense | -2.246M | -0.216M | -0.101M | 0.742M |
| Total Revenue | 16.401M | 0M | 0M | 0M |
| Total Operating Expenses | 72.457M | 50.087M | 22.404M | 9.936M |
| Cost Of Revenue | - | - | - | - |
| Total Other Income Expense Net | 2.246M | 0.104M | 7.364M | -0.312M |
| Net Income From Continuing Ops | -53.81M | -49.983M | -15.04M | -10.248M |
| Net Income Applicable To Common Shares | -53.81M | 101.959M | -28.217M | -18.229M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 |
|---|---|---|---|---|---|
| Total Assets | 126.929M | 174.833M | 160.245M | 179.25M | 96.398M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 2.071M | 2.677M | 3.957M | 3.537M | 0.344M |
| Total Liab | 53.539M | 63.459M | 37.908M | 26.463M | 148.261M |
| Total Stockholder Equity | 73.39M | 111.374M | 122.337M | 152.787M | -51.863M |
| Other Current Liab | 10.588M | 8.86M | 14.152M | 8.765M | 3.586M |
| Common Stock | 0.005M | 0.004M | 0.003M | 0.002M | 0.002M |
| Capital Stock | 0.005M | 0.004M | 0.003M | 0.002M | 0.002M |
| Retained Earnings | -414.588M | -344.073M | -306.705M | -252.895M | -51.865M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 0M | 10.885M | 1.857M | 0.362M |
| Cash | 110.995M | 134.343M | 129.315M | 157.531M | 92.57M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 15.18M | 19.378M | 23.989M | 11.874M | 5.284M |
| Current Deferred Revenue | - | 0.907M | 6.532M | - | - |
| Net Debt | -73.908M | -82.42M | -114.631M | -141.87M | -90.029M |
| Short Term Debt | 1.557M | 8.275M | 2.084M | 1.072M | 0.677M |
| Short Long Term Debt | - | 6.667M | - | - | - |
| Short Long Term Debt Total | 37.087M | 51.923M | 14.684M | 15.661M | 2.541M |
| Other Stockholder Equity | 487.973M | 455.443M | 429.039M | 405.68M | 0.175M |
| Property Plant Equipment | - | - | 8.988M | 16.325M | 3.122M |
| Total Current Assets | 113.066M | 138.37M | 140.2M | 161.068M | 92.914M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | - | - | - | - | - |
| Net Receivables | - | 1.35M | 6.928M | - | - |
| Long Term Debt | 26.095M | 32.656M | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | 3.035M | 1.336M | 1.221M | 2.037M | 1.021M |
| Accumulated Other Comprehensive Income | - | - | - | -179.25M | -0.175M |
| Non Currrent Assets Other | 1.54M | 0.594M | 2.594M | 1.857M | 0.362M |
| Non Current Assets Total | 13.863M | 36.463M | 20.045M | 18.182M | 3.484M |
| Capital Lease Obligations | 10.992M | 12.6M | 14.684M | 15.661M | 2.541M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|
| Investments | -3.611M | -0.498M | -0.56M | -0.266M |
| Total Cashflows From Investing Activities | -3.611M | -0.498M | -0.56M | -0.266M |
| Total Cash From Financing Activities | 15.906M | 109.427M | 93.857M | 21.909M |
| Net Income | -53.81M | -49.983M | -15.04M | -10.248M |
| Change In Cash | -28.301M | 66.053M | 74.673M | 12.101M |
| Begin Period Cash Flow | 158.83M | 92.777M | 18.104M | 6.003M |
| End Period Cash Flow | 130.529M | 158.83M | 92.777M | 18.104M |
| Total Cash From Operating Activities | -40.596M | -42.876M | -18.624M | -9.542M |
| Depreciation | 1.104M | 0.216M | 0.15M | 0.025M |
| Other Cashflows From Investing Activities | - | - | - | - |
| Dividends Paid | - | - | - | - |
| Change To Inventory | - | - | - | - |
| Sale Purchase Of Stock | 15.994M | 109.427M | - | - |
| Other Cashflows From Financing Activities | -0.285M | -2.173M | 93.857M | 21.907M |
| Capital Expenditures | 3.611M | 0.498M | 0.56M | 0.266M |
| Change In Working Capital | 2.539M | 2.277M | 2.308M | -0.711M |
| Other Non Cash Items | 2.171M | 0.519M | 0.627M | 0.95M |
| Free Cash Flow | -44.207M | -43.374M | -19.184M | -9.808M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 1 year ago | 895747 |
| 2. | iShares Russell 2000 ETF | 1 year ago | 643537 |
| 3. | Vanguard Institutional Extnd Mkt Idx Tr | 1 year ago | 392161 |
| 4. | Fidelity Small Cap Index | 1 year ago | 312004 |
| 5. | iShares Russell 2000 Value ETF | 1 year ago | 207257 |
| 6. | Fidelity Extended Market Index | 1 year ago | 170172 |
| 7. | Vanguard Russell 2000 ETF | 1 year ago | 151587 |
| 8. | A4Investments SICAV SIF ACCI IlanaA2EURH | 1 year ago | 117752 |
| 9. | Xtrackers Russell 2000 ETF 1C | 1 year ago | 101626 |
| 10. | Schwab Small Cap Index | 1 year ago | 95712 |
| 11. | State St Russell Sm/Mid Cp® Indx SL Cl I | 1 year ago | 92760 |
| 12. | NT R2000 Index Fund - NL | 1 year ago | 78469 |
| 13. | State St Russell Sm Cap® Indx SL Cl I | 1 year ago | 76900 |
| 14. | Vifag 2002 SICAV | 1 year ago | 70000 |
| 15. | iShares Russell 2000 Growth ETF | 1 year ago | 66696 |
| 16. | iShares Micro-Cap ETF | 1 year ago | 66135 |
| 17. | NT R2000 Index Fund - DC - NL - 3 | 1 year ago | 62686 |
| 18. | iShares Russell 2000 Small-Cap Idx Instl | 1 year ago | 60786 |
| 19. | Extended Equity Market Fund K | 1 year ago | 55918 |
| 20. | Fidelity Total Market Index | 1 year ago | 55085 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | RA Capital Management, LLC | 1 year ago | 6144881 |
| 2. | Mpm Asset Management, LLC | 1 year ago | 4284172 |
| 3. | Partner Fund Management LP | 1 year ago | 2905465 |
| 4. | MPM Oncology Impact Management LP | 1 year ago | 2408810 |
| 5. | Bank of America Corp | 1 year ago | 2078875 |
| 6. | BlackRock Inc | 1 year ago | 1671855 |
| 7. | Vanguard Group Inc | 1 year ago | 1509436 |
| 8. | Rubric Capital Management LP | 1 year ago | 1333893 |
| 9. | Geode Capital Management, LLC | 1 year ago | 702558 |
| 10. | Sphera Funds Management Ltd. | 1 year ago | 626810 |
| 11. | Millennium Management LLC | 1 year ago | 596289 |
| 12. | DC Funds, LP | 1 year ago | 589102 |
| 13. | State Street Corp | 1 year ago | 444272 |
| 14. | Northern Trust Corp | 1 year ago | 244390 |
| 15. | Alyeska Investment Group, L.P. | 1 year ago | 235705 |
| 16. | Morgan Stanley - Brokerage Accounts | 1 year ago | 138142 |
| 17. | Goldman Sachs Group Inc | 1 year ago | 111985 |
| 18. | Deutsche Bank AG | 1 year ago | 101626 |
| 19. | Walleye Trading Advisors, LLC | 1 year ago | 96850 |
| 20. | Charles Schwab Investment Management Inc | 1 year ago | 95712 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...